Flecainide Acetate is a Class IC antiarrhythmic pharmaceutical compound used in the management of certain cardiac rhythm disorders. It works primarily by slowing electrical conduction through the heart, particularly through the fast sodium channels responsible for cardiac depolarization. Flecainide acetate is commonly used under medical supervision for selected patients with paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation/flutter.
Flecainide Acetate API is supplied for pharmaceutical manufacturing and formulation applications. The API is suitable for qualified pharmaceutical manufacturers developing finished dosage forms according to applicable regulatory and quality requirements.
Flecainide Acetate belongs to the membrane-stabilizing Class IC group of antiarrhythmic agents. Its pharmacological action is associated with a dose-dependent reduction in cardiac conduction velocity, with a particularly pronounced effect on the His-Purkinje conduction system.
The compound is primarily associated with the prevention of selected symptomatic paroxysmal supraventricular tachycardias and paroxysmal atrial fibrillation/flutter in appropriate patients. It may also be used for prevention of certain documented life-threatening ventricular arrhythmias under specialist medical supervision.
Flecainide Acetate is used as an active ingredient in pharmaceutical formulations intended for the management and prevention of selected cardiac arrhythmias. Approved uses include prevention of symptomatic paroxysmal supraventricular tachycardias and paroxysmal atrial fibrillation/flutter in patients without structural heart disease.
It is also indicated for prevention of certain documented life-threatening ventricular arrhythmias when the treating physician determines that the potential benefits outweigh the risks.
Flecainide Acetate acts as a sodium-channel blocking antiarrhythmic agent. It decreases the rate of cardiac electrical conduction, with its strongest electrophysiological effect occurring in the His-Purkinje system. This action helps reduce abnormal electrical activity responsible for certain cardiac rhythm disturbances.
High-quality Flecainide Acetate API is an important raw material for pharmaceutical companies involved in the development and manufacturing of cardiovascular medicines. API procurement should be supported by appropriate quality documentation, analytical testing and regulatory compliance.
Depending on the intended market and application, documentation may include:
Flecainide Acetate API should be tested against the applicable approved product specification using validated analytical procedures. Important quality attributes may include identity, assay, related substances, residual solvents, water content, elemental impurities and other applicable pharmaceutical quality parameters.
For commercial pharmaceutical use, the final acceptance criteria should be based on the applicable pharmacopoeial, regulatory or manufacturer-approved specification rather than generic values.
Flecainide Acetate API should be stored in a tightly closed container under the storage conditions specified by the applicable product specification and supplier documentation. The material should be protected from unsuitable environmental conditions and handled in accordance with appropriate pharmaceutical safety procedures.
Flecainide Acetate API can be supplied in pharmaceutical-grade packaging suitable for bulk API handling. Packaging configuration should be selected according to batch size, transportation requirements, product stability and customer requirements.
Flecainide Acetate is an established pharmaceutical compound for selected cardiovascular applications. Reliable API sourcing can help pharmaceutical manufacturers maintain consistent raw-material quality, analytical traceability and production requirements.
When sourcing Flecainide Acetate API, pharmaceutical manufacturers should evaluate:
What is Flecainide Acetate API?
Flecainide Acetate API is the active pharmaceutical ingredient used in formulations containing flecainide for selected cardiac rhythm disorders.
What is Flecainide Acetate used for?
It is used for the prevention of certain symptomatic paroxysmal supraventricular tachycardias and paroxysmal atrial fibrillation/flutter, and in selected cases for prevention of life-threatening ventricular arrhythmias.
What class of antiarrhythmic is Flecainide Acetate?
Flecainide belongs to the Class IC group of antiarrhythmic agents.
Is Flecainide Acetate suitable for pharmaceutical manufacturing?
Yes. Flecainide Acetate is used as an API in pharmaceutical formulations, subject to applicable quality, regulatory and manufacturing requirements.
What quality documents are available for Flecainide Acetate API?
Depending on the supplier and market, documentation can include CoA, specifications, analytical reports and other applicable regulatory or technical documents.
How should Flecainide Acetate API be stored?
It should be stored according to the conditions specified in the applicable approved specification and supplier documentation.
Flecainide Acetate has clinically significant proarrhythmic risks and its use is restricted to appropriate medical situations. The information on this page is intended for pharmaceutical/API information and should not be interpreted as medical treatment advice.
Flecainide Acetate API, Flecainide Acetate API manufacturer, Flecainide Acetate manufacturer in India, Flecainide Acetate supplier, Flecainide Acetate API supplier, Flecainide Acetate pharmaceutical API, Flecainide Acetate bulk API, Flecainide Acetate active pharmaceutical ingredient, Flecainide API manufacturer India, cardiovascular API, antiarrhythmic API
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | NLT 98.0% by HPLC |
| Loss on Drying | NMT 0.5% |
| Residue on Ignition | NMT 0.2% |
| Heavy Metals | NMT 0.002% |
| Individual Impurity | NMT 0.50% |
| Total Impurities | NMT 2.0% |